"If requested, we will fully cooperate with the Chinese authorities," said a representative. The company remains committed to delivering its medicines despite the scrutiny.
Reports indicate a potential breach of patient privacy laws, with investigations into illegal data collection and drug imports focused on AstraZeneca's operations in China.
Collection
[
|
...
]